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Case Report
A Case of Laparoscopic Radical Prostatectomy for a Prostatic 
Stromal Tumor of Uncertain Malignant Potential 
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Prostatic stromal tumor of uncertain malignant potential (STUMP) is a rare neoplasm 
with distinctive clinical and pathological characteristics. Here we report a case of lapa-
roscopic radical prostatectomy performed in a patient with prostatic STUMP.
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Prostatic stromal tumor of uncertain malignant potential 
(STUMP) is a rare and distinctive proliferative lesion char-
acterized by an expansion of the specialized prostatic 
stroma. The clinical significance and management of 
STUMP is uncertain because of its rarity and the lack of 
long-term follow-up. Here we report the case of a patient 
with prostatic STUMP treated by laparoscopic radical 
prostatectomy (LRP) together with a review of literature.
CASE REPORT
A 44-year-old male visited our hospital because of abnor-
mal findings in a transrectal ultrasound (TRUS) of the 
prostate at another urology clinic. He presented with lower 
urinary tract symptoms (LUTS) including nocturia, uri-
nary frequency, and the sensation of incomplete emptying 
of the bladder that had persisted for several months. He 
had no specific medical or family history. In the digital rec-
tal examination, a 2 cm, tender, well-demarcated nodule 
was palpated in the left lobe of the prostate. The pros-
tate-specific antigen (PSA) value was 1.0 ng/ml, and the 
urine culture showed no urinary tract infection. TRUS of 
the prostate revealed a prostate volume of 28 ml with a 
mixed echogenic lesion (17 mm) in the left peripheral zone 
of the prostate. The prostate was biopsied under 
TRUS-guidance and classified as benign prostatic hyper-
plasia with fibrosis. After this diagnosis, the patient inter-
mittently took an alpha-blocker for his LUTS, which gradu-
ally were relieved. 
　Four years after the initial work-up of the prostate, the 
patient complained of aggravated LUTS (hesitancy and ab-
dominal straining). There were no abnormal findings in the 
serum PSA level and urinalysis. TRUS of the prostate dem-
onstrated a 35 mm heterogeneous echogenic lesion with an 
interval increase of size in the left peripheral zone of the 
prostate (Fig. 1A). The patient underwent TRUS-guided 
needle biopsy of the prostate with 12 cores. Pathological ex-
amination showed a spindle cell proliferative lesion with 
focal hypercellularity and moderate cellular atypia in mul-
tiple cores of the left prostatic lobe, favoring a malignant 
tumor. On immunohistochemical study, the atypical stro-
mal cells displayed intense cytoplasmic immunoreactivity 
for vimentin and no significance for Ki-67. Prostate mag-
netic resonance imaging (MRI) revealed a 4.0 cm mass orig-
inating from the left lobe of the prostate without ex-
tracapsular extension (Fig. 1B) and a 11 mm lymph node 
in the right common iliac chain that was assumed to be a 
metastatic lesion. To differentiate this lesion from prostate 
sarcoma and to treat the severe LUTS of the patient, we 
decided to perform LRP. 
　Preoperatively, the International Index for Erectile 
Function Questionnaire-5 (IIEF-5) score of the patient was Korean J Urol 2011;52:578-581
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FIG. 1. (A) Transrectal ultrasound of 
the prostate showing a 35 mm hetero-
geneous echogenic lesion in the left 
peripheral zone of the prostate. (B) 
Prostate magnetic resonance imaging 
(MRI): A 4.0 cm mass originated from 
the left lobe of the prostate without 
extracapsular extension.
FIG. 2. Gross appearance of the prostate.
13, indicating mild to moderate erectile dysfunction, and 
he needed medication to maintain an erection for sat-
isfactory sexual intercourse. We performed LRP with 
standard pelvic lymph node dissection; the right neuro-
vascular bundle was spared and the left neurovascular 
bundle was widely excised. The total operative time was 
250 minutes, and the amount of blood loss was 300 ml. The 
urethral Foley catheter was removed on day 7 after sur-
gery, and the patient was discharged without any specific 
postoperative complications on day 8. Grossly, the prostate 
lesion was a well circumscribed mass, of which the largest 
measured 38x30 mm, containing dilated spaces (Fig. 2). 
The final pathologic results showed prostatic STUMP with 
moderate cellularity and marked pleomorphism, lack of 
mitotic figures, necrosis, and stromal overgrowth (Fig. 3). 
There was no tumor involvement in the pelvic lymph nodes. 
The weight of the prostate was 39 g, the tumor involved the 
left lobe within the capsule, and the resection margin was 
clear. The patient has been continent (never used pad) and 
capable of sexual intercourse with medication with tadala-
fil 20 mg since 6 months postoperatively. At the 24-month 
postoperative follow-up, there was no evidence of disease 
recurrence. 
DISCUSSION
Stromal tumor of the prostate is a rare prostatic neoplasm 
that comprises a variety of forms with different histo-
pathology. It has distinctive clinical and pathological char-
acteristics and has been referred to by various terms, in-
cluding atypical stromal hyperplasia, phyllodes type of 
atypical stromal hyperplasia, cystic epithelial-stromal tu-
mor, prostatic stromal tumor of uncertain malignant po-
tential, and cystosarcoma phyllodes [1]. Gaudin et al ana-
lyzed stromal tumors of the prostate to define a spectrum 
of histologic features [2]. The results of their study showed 
that stromal tumors of the prostate could be classified into 
prostatic STUMP and prostatic stromal sarcoma on the ba-
sis of the degree of cellularity and the presence of mitotic 
figures, necrosis, and stromal overgrowth. Prostatic sarco-
ma, of which histologic grade is predictive of patient out-
come, is likely to develop local recurrence and distant meta-
stasis, whereas the natural history of STUMP is uncertain. 
According to previous reports in the literature on follow-up 
studies of prostate stromal tumors, some authors recom-
mended that the use of the term STUMP be discouraged 
because of its benign course and rare recurrence [3]. 
Others, meanwhile, reported that these tumors usually re-
curred and frequently showed the emergence of metastatic 
disease, and insisted on complete resection at the initial di-
agnosis [4]. Table 1 illustrates the various clinical courses 
of prostatic stromal tumors according to the prior literature 
[5-8]. Histological patterns of prostatic STUMP have been 
identified on the basis of stromal cellularity, the presence 
of atypia, and the appearance of nonneoplastic glandular 
elements. Prostatic STUMP is a histologically unique neo-
plasm associated with sarcoma, either concurrently or sub-
sequently, indicating unpredictable behavior. In addition, 
the biopsy or transurethral resection (TUR) specimens 
showed the feature of a STUMP with atypia, yet the re-
sected specimen showed not only STUMP but also areas 
with increased cellularity and increased mitotic activity, Korean J Urol 2011;52:578-581
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FIG. 3. Hematoxylin-eosin staining of 
prostatectomy specimen showing (A) 
moderate cellularity and (B) marked 
atypical cells in the stroma and around
benign acini (A: x100, B: x400).
TABLE 1. Stromal tumors of the prostate reported in the literature
Reference Clinical presentation Diagnosis Treatment Follow-up (months) Outcome
Klausner et al [8]
Bannowsky et al [5]
Fukuhara et al [7]
Colombo et al [6]
LUTS
LUTS
Elevated PSA
LUTS
STUMP
PT
STUMP
STUMP, HG PSS
TURP
TURP
RP
RP, RT, CT
36
18
10
25
Recurrence
NED
NED
DOD
LUTS: lower urinary tract symptoms, PSA: prostate-specific antigen, STUMP: stromal tumor of uncertain malignant potential, PT:
phyllodes tumor, HG: high-grade, PSS: prostatic stromal sarcoma, TURP: transurethral resection of the prostate, RP: radical prostatec-
tomy, RT: radiotherapy, CT: chemotherapy, NED: no evidence of disease, DOD: dead of disease
diagnostic of stromal sarcoma in some cases [9]. Histologi-
cal features, including stromal cellularity, cytologic atypia, 
the number of mitotic figures per 10 high power fields, stro-
mal-to-epithelial ratio, and necrosis have been quantified 
to assign a tumor grade and predict patient outcome. Close 
surveillance with cystoscopy and TRUS after TUR might 
be an alternative option to achieve local control in 
low-grade tumors [5]. However, tumor recurrence after 
TUR is common, and these tumors are often locally ag-
gressive with time, showing frequent sarcomatous trans-
formations as multiple recurrences occur [4]. Herawi and 
Epstein recommended definitive surgical resection in 
younger patients owing to the unpredictability of STUMP 
and the lack of correlation between histologic patterns and 
sarcomatous dedifferentiation [9], considering expectant 
management with close follow-up in older patients without 
lesions on the DRE or imaging studies. Most prostatic stro-
mal tumors develop in the posterior portion of the gland, 
where they can adhere to adjacent organs or present retro-
vesical mass [10]. 
　In our case, the patient had suffered from LUTS, occur-
ring at a younger age than expected for typical benign pro-
static hyperplasia. TRUS of the prostate revealed the in-
creasing size of the lesion originating from the peripheral 
zone of the prostate. Patient age was an important factor 
in our decision for radical surgery to differentiate a pro-
static lesion from a prostatic sarcoma, because Herawi and 
Epstein reported that men with prostatic sarcoma tend to 
be younger at presentation [9]. Immunohistochemical 
staining in the prostatectomy specimen revealed a focal 
positivity for CD34. Prostatic STUMP is a rare neoplasm 
with unique local morbidity and malignant potential; 
therefore, its recognition by urologists is essential. This 
case shows that a patient with prostatic STUMP treated 
by LRP has had tolerable oncologic and functional out-
comes until the final follow-up. It might be valuable to 
study the clinical significance of this case through further 
long-term follow-up. 
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